According to a systematic review, improvement can occur in 55.2% of patients after a median of two (one to six) bortezomib cycles. agents (such as bortezomib and daratumumab); and (3) treatments targeting intrathecal immune cells or their trafficking through the bloodCbrain barrier (such as intrathecal methotrexate and natalizumab). The efficacy evidence of these drugs is mostly based on case reports or small case series, with few reported controlled studies or ARRY334543 (Varlitinib) systematic reviews. The aim of the present review is to summarize the current evidence and related methodological issues in the use of these drugs for the treatment of refractory autoimmune encephalitis. Key Points A minority of patients with autoimmune encephalitis may remain refractory even to second-line therapies and they represent a major clinical challenge. In these cases, treatment strategies are controversial, and no guidelines exist.Treatments proposed for refractory autoimmune encephalitis include cytokine-based drugs, plasma cell-depleting agents, and treatments targeting intrathecal immune cells or their trafficking through the bloodCbrain barrier.The evidence of efficacy of these treatments is mostly based on case reports or small case series, controlled studies and systematic reviews are rare. Open in a separate window Introduction In recent years, the advances in the diagnostic assays ARRY334543 (Varlitinib) and the recognition of novel clinical syndromes have helped to define the new emerging field of autoimmune neurology. Autoimmune encephalitides (AEs) represent a broad spectrum of immune-mediated and potentially treatable disorders that are currently being more frequently recognized. The underlying pathogenesis of these conditions is related to the presence of pathogenic antibodies directed against neuronal cell surface antigens or to a T-cell-mediated process in paraneoplastic disorders associated with non-pathogenic antibodies directed against intracellular targets [1, 2]. Prompt immunotherapy [3, 4] is the mainstay of AEs treatment and includes first-line and second-line medications. Intravenous steroids [5, 6], intravenous immunoglobulins [7], and plasma exchange [8] represent first-line immunotherapies. These treatments may be administered sequentially or in association, in particular steroids and plasma exchange/intravenous immunoglobulins, in the case of rapidly progressive or severe symptoms at onset [9]. Second-line treatment should be subsequently administered in the case of no clinical improvement after 2C4 weeks of first-line immunotherapy [10]. Rituximab and cyclophosphamide are the most frequently administered treatments. In particular, cyclophosphamide is preferred over rituximab in paraneoplastic disorders, as it depletes T cells, crosses the bloodCbrain barrier (BBB), and may be part of the oncological treatment scheme [11]. Antibody specificity also influences treatment choices, as demonstrated by the different response to rituximab in patients with antibodies to = 60) Anti-NMDAR encephalitis (= 26 + 52) LGI1 encephalitis (=3) GAD-65 encephalitis (=1) CASPR2 encephalitis (= 2) Anti-amphiphysin encephalitis (= 2) Intravenous, 8 mg/kg monthly (4C6, reduced dose, or 2C4, split dose, in the case of an increased risk of hematological or infectious complications)Pre-treatment: tuberculosis test, complete blood count, liver function, lipid panel Monitor: complete blood count, liver function, lipid panel Monitor for signs of infection, new-onset abdominal pain and demyelinating disorders Gastrointestinal (constipation), increased serum cholesterol, neutropenia, increased liver Rabbit polyclonal to DNMT3A enzymes, injection-site and infusion-site reactions, increased risk of infection Warning for gastrointestinal perforation and demyelinating disorders [19C24]Low-dose Interleukin-2Stimulates T-regulatory lymphocytesAnti-NMDAR encephalitis (= 4) Seronegative autoimmune encephalitis (= 6) Subcutaneous, one cycle of IL-2 (1.5 million IU/day) of 5 days, followed by three 5-day cycles of 3 million IU/dayComplete blood count, renal and liver function, electrolytes, chest x-ray, ECG, vital signs daily during infusion Thyroid-stimulating hormone every 2C3 months Flu-like syndrome, flushing, hypotension, tachycardia/arrythmia, diarrhea and vomiting, cytopenia, capillary leak syndrome, altered liver and renal function, confusion/lethargy, infections[26]BasiliximabMonoclonal antibody against interleukin-2 receptor alpha chain (exerts its effect on T-effector lymphocytes)GAD-65 limbic encephalitis (= 1)Intravenous, 20 mg monthlyMonitor for infections, hypersensitivity, and electrolytesHypertension, edema, metabolic disturbances (hyperglycemia, hypercholesterolemia, hyperuricemia), electrolyte disturbances (hyperkalemia, hypokalemia, hypophosphatemia), anemia, gastrointestinal (pain, diarrhea, constipation, nausea, vomiting), increased risk of infections[27]AnakinraInterleukin-1 antagonistSeronegative limbic encephalitis (= 1) Seronegative autoimmune encephalitis (= 1) Anti-NMDAR encephalitis (animal model) Subcutaneous, 100 mg dailyPre-treatment: complete blood count, creatinine, tuberculosis test Monitor: complete blood count, creatinine, signs of infection Vomiting, ARRY334543 (Varlitinib) infections (bone/joint infections, pneumonia, cellulitis, nasopharyngitis), headache, local injection ARRY334543 (Varlitinib) reaction[29C31]TofacitinibJAK1 and JAK3 inhibitorAnti-NMDAR encephalitis (= 2) GAD-65 encephalitis (= 2) MOGAD encephalitis (= 2) Seronegative autoimmune encephalitis (= 4) Oral, 5 mg twice dailyPre-treatment: complete blood count, lipids, viral hepatitis, renal and liver function, tuberculosis test Monitor: complete blood count, renal and liver function Monitor for signs of infection, abdominal symptoms, vital signs, skin examination Infections, bone marrow suppression, gastrointestinal perforations, increased liver enzymes, hypersensitivity, lipid abnormalities, possible increased risk of malignancy and interstitial lung disease[32]Bortezomib26s proteasome inhibitorAnti-NMDAR encephalitis (= 1) Intravenous or subcutaneous infusion, 1.3 mg/m2 per cyclePre-treatment: caution is required in patients with pre-existing cardiovascular disorders Complete blood count, blood glucose, renal and liver function, hepatitis virus screening, chest x-ray Monitor: complete blood count, blood glucose (if history of diabetes mellitus), renal and liver function Monitor blood pressure, pulmonary function testing and signs of peripheral neuropathy or progressive multifocal leukoencephalopathy Requires prophylaxis for mitigating.